Ocular Therapeutix (OCUL)
(Delayed Data from NSDQ)
$5.51 USD
-0.19 (-3.33%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $5.51 0.00 (0.00%) 6:08 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Ocular Therapeutix, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 196 | 102 | 164 | 228 | 54 |
Receivables | 26 | 21 | 21 | 12 | 3 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 2 | 2 | 1 | 1 | 1 |
Other Current Assets | 8 | 4 | 5 | 5 | 2 |
Total Current Assets | 232 | 130 | 191 | 246 | 60 |
Net Property & Equipment | 12 | 10 | 7 | 8 | 10 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 2 | 2 | 2 | 2 |
Total Assets | 252 | 149 | 205 | 262 | 79 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 8 | 0 |
Accounts Payable | 4 | 5 | 5 | 3 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 29 | 24 | 20 | 14 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 0 | 0 | 0 |
Total Current Liabilities | 35 | 31 | 26 | 27 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 14 | 13 | 13 | 12 | 0 |
Convertible Debt | 9 | 29 | 26 | 24 | 24 |
Long-Term Debt | 66 | 25 | 25 | 17 | 25 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 30 | 6 | 20 | 98 | 12 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 161 | 114 | 117 | 186 | 82 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 789 | 652 | 634 | 615 | 380 |
Retained Earnings | -698 | -617 | -546 | -539 | -384 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 91 | 35 | 88 | 76 | -4 |
Total Liabilities & Shareholder's Equity | 252 | 149 | 205 | 262 | 79 |
Total Common Equity | 91 | 35 | 88 | 76 | -4 |
Shares Outstanding | 114.90 | 77.00 | 76.60 | 75.80 | 48.00 |
Book Value Per Share | 0.79 | 0.46 | 1.15 | 1.00 | -0.08 |
Fiscal Year End for Ocular Therapeutix, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 483 | 196 | 111 | 67 | 79 |
Receivables | 27 | 26 | 24 | 27 | 21 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3 | 2 | 2 | 2 | 2 |
Other Current Assets | 8 | 8 | 5 | 5 | 5 |
Total Current Assets | 520 | 232 | 141 | 101 | 107 |
Net Property & Equipment | 11 | 12 | 12 | 13 | 12 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 2 | 2 | 2 | 2 |
Total Assets | 539 | 252 | 162 | 123 | 129 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 2 | 0 |
Accounts Payable | 6 | 4 | 4 | 4 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 16 | 29 | 29 | 25 | 22 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 24 | 35 | 35 | 32 | 30 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 14 | 14 | 14 | 14 | 13 |
Convertible Debt | 0 | 9 | 9 | 30 | 29 |
Long-Term Debt | 66 | 66 | 65 | 23 | 25 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 20 | 24 | 12 | 13 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 131 | 161 | 155 | 119 | 119 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,170 | 789 | 676 | 671 | 657 |
Retained Earnings | -762 | -698 | -668 | -668 | -647 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 408 | 91 | 8 | 3 | 10 |
Total Liabilities & Shareholder's Equity | 539 | 252 | 162 | 123 | 129 |
Total Common Equity | 408 | 91 | 8 | 3 | 10 |
Shares Outstanding | 154.70 | 114.90 | 79.30 | 77.50 | 77.50 |
Book Value Per Share | 2.64 | 0.79 | 0.10 | 0.04 | 0.13 |